Merck KGaA is no longer pursuing clinical-stage candidates obtained through its $3.9 billion acquisition of SpringWorks, which centered on approved drugs.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its $3.9 billion acquisition of SpringWorks, which centered on approved drugs.